WallStreetZenWallStreetZen

How to Buy Apellis Pharmaceuticals Stock

Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals, Inc. , a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases.

Apellis Pharmaceuticals stock last closed at $47.51, down 1.08% from the previous day, and has decreased 42.17% in one year. It has underperformed other stocks in the Biotechnology industry by 0.16 percentage points. Apellis Pharmaceuticals stock is currently +139.59% from its 52-week low of $19.83, and -49.86% from its 52-week high of $94.75.

As of Apr 18, 2024, there are 120.58M shares of APLS outstanding. The market cap of APLS is $5.73B. In the last 24 hours, 1.84M APLS shares were traded.

How to Buy Apellis Pharmaceuticals Stock

Wondering how to invest in Apellis Pharmaceuticals stock? Here's how.
  1. Decide where to buy Apellis Pharmaceuticals stock: You need to pick an online brokerage, but don't worry - we've tried dozens of online stock brokerages and apps to help you decide where to buy Apellis Pharmaceuticals stock.
  2. Sign up for a brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've found.
  3. Deposit money your investment account: Choose your method of payment and add your info.
  4. Analyze Apellis Pharmaceuticals stock: The Apellis Pharmaceuticals ticker symbol is APLS. Is Apellis Pharmaceuticals stock a good investment? Should you buy shares of APLS? How do APLS's underlying business fundamentals look? Do top analysts think Apellis Pharmaceuticals is a good buy? Why has APLS's stock price moved recently? (Hint: Our stock analysis website can help you understand if APLS is a good stock to buy).
  5. Execute your APLS trade: Decide if you will purchase APLS shares at the current market price or use a limit order to buy APLS shares at a specific price.
  6. Keep tabs on your APLS position: Create a watchlist to the latest updates on your investment in Apellis Pharmaceuticals shares.

Step 1: Decide where to buy Apellis Pharmaceuticals stock

You need a brokerage account in order to access the NASDAQ market and buy APLS stock.

A brokerage account allows you to buy and sell a number of investments, such as stocks, bonds, mutual funds, and ETFs.

Our preferred brokerage: eToro

We believe that eToro is the best brokerage. Here's why:

  • Invest in stocks with 0% commissions: Invest without paying trading commissions.
  • Buy fractional shares: Even if you don't have the money to buy a full share, you can still purchase the stock.
  • Access to world financial markets: From Technology to Healthcare, New York to Tokyo — you can fill your portfolio with stocks from the world's leading exchanges.
  • Social investing: eToro offers a community with more than 20 million users worldwide. Talk to, learn from, and copy the unique crypto portfolios of other investors.
  • Security: eToro is a regulated and licensed fintech leader.
  • Buy other assets: Such as ETFs and cryptos.

Get $10 towards your stock purchase by opening an account with eToro now.

Open eToro Account
eToro securities trading is offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency is offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. https://www.wallstreetzen.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD.

Step 2: Sign up for a brokerage account

Now that you've selected the right brokerage, you'll need to fill out some personal info so you can buy APLS stock today.

How to Open a New Brokerage Account on eToro

  1. Click here to get started.
    eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
  2. Input your personal info to create your new trading account.
  1. Send your information by clicking the "Create Account" button.
  2. Get started with eToro today
    eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.

Step 3: Deposit money your investment account

Now that you have finished signing up on the best stock app for beginners, you need to deposit funds:

Watch the walkthrough below for more details depositing funds into your new investment account.

Get started with eToro today
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.

Step 4: Analyze Apellis Pharmaceuticals stock

After you have decided on the best place to buy Apellis Pharmaceuticals stock, it's crucial to evaluate their stock prior to buying, so you can wrap your head around the risk and opportunity.

Overview of key APLS info

APLS Price
$47.51
1w %
-14.75%
1y %
-42.17%
5y %
151.64%
P/E
-10.68x
P/B
29.45x
P/S
14.22x
PEG
N/A
Revenue
$396.59M
Earnings
-$528.63M
Fore. Rev. Growth
58.26%
Fore. Earn. Growth
N/A
Market Cap
$5.73B
Next Earnings
May 2, 2024
Next Dividend
N/A

APLS Fundamentals

WallStreetZen was created to help part-time investors do more in-depth fundamental analysis quickly.

You can view all of the due diligence checks on APLS's stock page.

Is APLS stock properly valued?

Investors use a variety of different financial metrics, analyses, models, and charts to gauge APLS's fair value.

Using relative valuations methods:

  • APLS may be overvalued based on its P/B ratio of 29.45x, relative to Biotechnology industry P/B ratio of 5.76x

You can access additional valuation research on APLS's stock here.

APLS Financial Health Summary

Passed Health Checks:

  • There are more short-term assets than short-term liabilities on the APLS balance sheet.
  • There are more short-term assets than long-term liabilities on the APLS balance sheet.

Failed Health Checks:

  • APLS profit margin has gone up by 7.31 percentage points in the past year, but the company is still unprofitable.
  • Total APLS debt is higher than 5 years ago, relative to shareholder equity.
  • APLS has cash burn of 595409000. It does not have enough cash and short-term investments to cover this.
  • APLS has a relatively high debt to equity ratio of 3.06.
  • APLS has $352.30M in cash and short term investments. This is not enough to cover its annual cash burn of $595.41M.

Is it a good time to buy APLS stock, according to analysts?

Out of 14 sell side analysts who give ratings on APLS, the consensus analyst rating on APLS is a Strong Buy

Please keep in mind that analyst ratings are not recommendations, nor are they investment advice.

Most Recent APLS Analyst Ratings

Eliana Merle, a top 20% analyst from UBS maintains APLS with a strong buy rating and raises their APLS price target from $87.00 to $89.00, on Mar 4, 2024.

UBS's Eliana Merle raised their price target on Apellis Pharmaceuticals (NASDAQ: APLS) by 2.3% from $87 to $89 on 2024/03/04. The analyst maintained their Strong Buy rating on the stock.

Harkening back to Apellis Pharmaceuticals' Q4 and FY 2023 earnings, reported on 2024/02/27, Merle said that "management's color on Q1 2024 sales trends increases UBS's conviction in the ongoing Geographic Atrophy commercial launch and their firm expects continued revenue growth in Q1 and beyond."

Apellis Pharmaceuticals is a revenue growth story from here, the analyst argued, saying they see "additional potential upside for the stock from Phase 3 C3 glomerulopathy/immune-complex membranoproliferative glomerulonephritis topline data, expected in mid-2024."

Colleen Kusy, a bottom 4% analyst from Baird reiterates APLS with a buy rating and maintains their APLS price target from $81.00 to $81.00, on Feb 6, 2024.

Akash Tewari, a top 25% analyst from Jefferies upgrades APLS to a strong buy rating and raises their APLS price target from $68.00 to $80.00, on Feb 5, 2024.

Justin Kim, a top 21% analyst from Oppenheimer maintains APLS with a buy rating and raises their APLS price target from $75.00 to $79.00, on Jan 30, 2024.

Steven Seedhouse, a top 11% analyst from Raymond James maintains APLS with a strong buy rating and raises their APLS price target from $67.00 to $106.00, on Jan 11, 2024.

You can dig deeper into what analysts are forecasting on the Apellis Pharmaceuticals stock forecast page.

APLS Technicals

SMA10
52.81
SMA20
55.01
SMA50
60.27
SMA100
60.89
SMA200
52.59
MACD
-2.79
MACD Signal
-2.15
MACD Histogram
-0.64
RSI
28.97
Stochastic %K
8.86
Stochastic %D
12.14
StochRSI %K
2.53
StochRSI %D
2.68

APLS Growth Numbers

Last year, APLS revenue was $396.59M. In the last 3 year, APLS's revenue has gone up by 83.5% per year. This was faster than the Biotechnology industry average of 28.98%.

You can research APLS's earnings and revenue performance here.

Who is buying/selling APLS?

Over the last 12 months, executives and large shareholders at APLS have bought more shares than they have sold.

A. Sinclair Dunlop, Director of APLS, was the latest APLS insider to buy. They bought $19,785.00 worth of APLS stock on Apr 12, 2024.

Research more about who owns APLS shares here.

Can I rely on APLS as an income stream?

No, Apellis Pharmaceuticals doesn't provide an income stream by paying out dividends.

What do other investors have to say about APLS?

One of the major reasons eToro is our favorite brokerage is because of its social trading community.

Click below to find out what other community members have to say.

Step 5: Execute your APLS trade

There are two primary order types:

  • Market order: A market order is an order to buy or sell a stock at the best possible price.
    Market orders are usually sufficient.
  • Limit order: A limit order enables you to buy or sell a security at a specific price (or better).
    If you want to make sure you're buying or selling at a particular dollar amount, place a limit order.

Click the Open button and eToro will execute your order.

If you need more help buying stocks on eToro, click the helpful video below:

Open eToro Account

Step 6: Keep tabs on your APLS position

Now that you own some shares in APLS, you'll want to stay up-to-date on your stock purchase.

Start a watchlist to keep tabs on your APLS stock.

APLS Feed

How to Buy Stock in Apellis Pharmaceuticals

To reiterate, here are the 6 steps you need to take to buy Apellis Pharmaceuticals stock right now:

  1. Decide where to buy Apellis Pharmaceuticals stock
  2. Sign up for a brokerage account
  3. Deposit money your investment account
  4. Analyze Apellis Pharmaceuticals stock
  5. Execute your APLS trade
  6. Keep tabs on your APLS position

If you require a brokerage, eToro is our favorite venue.

Get Started with eToro Today
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.

If you would like to get updates on your new investment in Apellis Pharmaceuticals, click the button below.

NASDAQ: APLS
$47.51-0.52 (-1.08%)
Updated Apr 18, 2024
Open eToro Account
NASDAQ: APLS
$47.51-0.52 (-1.08%)
Updated Apr 18, 2024
Open eToro Account

FAQ

How much does it cost to buy one Apellis Pharmaceuticals share?

As of Apr 18, 2024, it costs $47.51 to buy one share of Apellis Pharmaceuticals stock.

Remember, eToro's fractional share buying allows you to buy partial shares of stocks and ETFs. Even if you only have $10, you can buy 0.21 shares of APLS.

Get Started with eToro Today
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.

Is now a good time to buy Apellis Pharmaceuticals stock?

According to 14 Wall Street analysts who monitor Apellis Pharmaceuticals, their consensus recommendation is to buy Apellis Pharmaceuticals stock.

What is the best way to buy Apellis Pharmaceuticals stock?

One way to place an order for Apellis Pharmaceuticals stock is with a brokerage account.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.